July 18, 2023 News by Marisa Wexler, MS With Korro Bio merger in works, Frequency stops program for MS With a planned merger in the works, Frequency Therapeutics is no longer advancing its remyelination therapies for multiple sclerosis (MS), and instead is exploring “strategic alternatives for the program,” the company has announced. The regenerative medicine company, which had aimed to develop a new approach to treating MS…
December 7, 2021 News by Marisa Wexler, MS Worsening of Disability Evident in Older Patients Who Stop DMTs While older multiple sclerosis (MS) patients whose conditions are stable commonly stop using disease-modifying therapies (DMTs), a study indicates this decision can shortly lead toĀ a marked disease worsening in a substantial portion of them. “Our results raise important questions about the accepted practice of discontinuing medications once MS…
August 10, 2020 News by Patricia Inacio, PhD 1 in 5 MS Patients Don’t Adhere to Daily Oral DMTs, Real-world Study Finds About 20%, or 1 in 5,Ā multiple sclerosis (MS) patients fail to adhere to oral disease-modifying therapies (DMTs) taken each day, and about 1 in 4 stop using a prescribed daily oral treatment within one year, a study based on reported real-world use found. The study āReal-world adherence to,…
January 30, 2019 News by Jonathan Grinstein Canadian RRMS Patients Less Likely to Discontinue Treatment with Oral Gilenya, Compared to Injectable or Infusible Therapies Multiple sclerosisĀ (MS) patients in Canada are more likely to comply with their treatment plan and less likely to discontinue the use of the oral disease-modifying treatment Gilenya (fingolimod), compared to injectable or infusible treatment options, new research shows. The research article with that finding, āA…
April 4, 2018 News by Diogo Pinto Two Factors Lead to Better Outcomes when Disease-modifying Therapies Stopped, Study Finds A lot of people withĀ multiple sclerosisĀ take disease-modifying therapies to reduce the inflammation associated with the disease ā but in many patients, the treatments’ effectiveness wanes at a certain points. When that occurs, the question is whether to stop taking these treatments, known as DMTs. A study reports that patients’…
August 10, 2017 News by Patricia Inacio, PhD Botulinum Toxin Treats MS Spasticity, But Support and Rehab Seen as Crucial to Long-term Use Spasticity in multiple sclerosis patients can be eased through a combination of botulinum toxin type A (BoNT-A) injections and rehabilitation. However, caregiver support is required to keep patients on this treatment, according to results of a retrospective analysis. Spasticity, a muscle control disorder characterized by tight or stiff muscles, is a major MS symptom. The condition is significantly detrimental to patientsā quality of life, affecting their general mobility and balance. Several oral anti-spasticity drugs are available. However, ātreatment of spasticity in MS is frequently challenging because of the complex clinical picture and the undesired effects associated with oral therapy, such as fatigue, dizziness, and hypotension,ā the researchers wrote. Previous studies show that BoNT-A, a toxin that blocks nerve activity in muscles, is an effective therapy for the management of MS-related spasticity. The long-term effectiveness and persistence of BoNT-A use in patients with MS-related spasticity, however, remains poorly investigated. The research team in Italy proposed āto investigate the long-term persistence to treatment with BoNT-A for MS-related spasticity and the determinants of BoNT-A discontinuation in daily clinical setting.ā In total, the researchers reviewed data from 185 patients, out of which 121 were considered in their final analysis. They observed that, at the end of the follow-up period, 44% of the patients in the analysis were still being treated with BoNT-A, but 56% had discontinued treatment. Overall, these results āconfirm the beneficial effect of combining BoNT-A injections with rehabilitation and highlights the crucial role of caregivers for achieving better long-term outcomes in people with MS suffering from spasticity,ā the team concluded.
May 30, 2017 News by Patricia Silva, PhD #CMSC17 – Review Suggests Certain MS Patient Groups May Discontinue Disease-Modifying Treatments Older patients with secondary progressive multiple sclerosis (SPMS) as well as older relapsing patients whose MS has been inactive after five years may safely discontinue their treatments, Canadian researchers at Vancouver’sĀ University of British ColumbiaĀ argue. TheirĀ Sanofi Genzyme-sponsoredĀ study, āWhen Should Disease-Modifying Treatments Be Discontinued in Patients with Multiple Sclerosis: An…